615 related articles for article (PubMed ID: 23742737)
1. A double-blind, placebo-controlled, crossover pilot trial with extension using an oral mucosal cannabinoid extract for treatment of chemotherapy-induced neuropathic pain.
Lynch ME; Cesar-Rittenberg P; Hohmann AG
J Pain Symptom Manage; 2014 Jan; 47(1):166-73. PubMed ID: 23742737
[TBL] [Abstract][Full Text] [Related]
2. Results of a Double-Blind, Randomized, Placebo-Controlled Study of Nabiximols Oromucosal Spray as an Adjunctive Therapy in Advanced Cancer Patients with Chronic Uncontrolled Pain.
Lichtman AH; Lux EA; McQuade R; Rossetti S; Sanchez R; Sun W; Wright S; Kornyeyeva E; Fallon MT
J Pain Symptom Manage; 2018 Feb; 55(2):179-188.e1. PubMed ID: 28923526
[TBL] [Abstract][Full Text] [Related]
3. A double-blind, randomized, placebo-controlled, parallel-group study of THC/CBD oromucosal spray in combination with the existing treatment regimen, in the relief of central neuropathic pain in patients with multiple sclerosis.
Langford RM; Mares J; Novotna A; Vachova M; Novakova I; Notcutt W; Ratcliffe S
J Neurol; 2013 Apr; 260(4):984-97. PubMed ID: 23180178
[TBL] [Abstract][Full Text] [Related]
4. A multicentre, open-label, follow-on study to assess the long-term maintenance of effect, tolerance and safety of THC/CBD oromucosal spray in the management of neuropathic pain.
Hoggart B; Ratcliffe S; Ehler E; Simpson KH; Hovorka J; Lejčko J; Taylor L; Lauder H; Serpell M
J Neurol; 2015 Jan; 262(1):27-40. PubMed ID: 25270679
[TBL] [Abstract][Full Text] [Related]
5. A phase 1b randomised, placebo-controlled trial of nabiximols cannabinoid oromucosal spray with temozolomide in patients with recurrent glioblastoma.
Twelves C; Sabel M; Checketts D; Miller S; Tayo B; Jove M; Brazil L; Short SC;
Br J Cancer; 2021 Apr; 124(8):1379-1387. PubMed ID: 33623076
[TBL] [Abstract][Full Text] [Related]
6. A double-blind, randomized, placebo-controlled, parallel group study of THC/CBD spray in peripheral neuropathic pain treatment.
Serpell M; Ratcliffe S; Hovorka J; Schofield M; Taylor L; Lauder H; Ehler E
Eur J Pain; 2014 Aug; 18(7):999-1012. PubMed ID: 24420962
[TBL] [Abstract][Full Text] [Related]
7. Tetrodotoxin for Chemotherapy-Induced Neuropathic Pain: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Dose Finding Trial.
Goldlust SA; Kavoosi M; Nezzer J; Kavoosi M; Korz W; Deck K
Toxins (Basel); 2021 Mar; 13(4):. PubMed ID: 33805908
[TBL] [Abstract][Full Text] [Related]
8. Tetrahydrocannabinol and cannabidiol oromucosal spray in resistant multiple sclerosis spasticity: consistency of response across subgroups from the SAVANT randomized clinical trial.
Meuth SG; Henze T; Essner U; Trompke C; Vila Silván C
Int J Neurosci; 2020 Dec; 130(12):1199-1205. PubMed ID: 32065006
[No Abstract] [Full Text] [Related]
9. An enriched-enrolment, randomized withdrawal, flexible-dose, double-blind, placebo-controlled, parallel assignment efficacy study of nabilone as adjuvant in the treatment of diabetic peripheral neuropathic pain.
Toth C; Mawani S; Brady S; Chan C; Liu C; Mehina E; Garven A; Bestard J; Korngut L
Pain; 2012 Oct; 153(10):2073-2082. PubMed ID: 22921260
[TBL] [Abstract][Full Text] [Related]
10. The Efficacy of Pregabalin in the Treatment of Prediabetic Neuropathic Pain.
González-Duarte A; Lem M; Díaz-Díaz E; Castillo C; Cárdenas-Soto K
Clin J Pain; 2016 Nov; 32(11):927-932. PubMed ID: 26670614
[TBL] [Abstract][Full Text] [Related]
11. Long-term effectiveness and safety of nabiximols (tetrahydrocannabinol/cannabidiol oromucosal spray) in clinical practice.
Flachenecker P; Henze T; Zettl UK
Eur Neurol; 2014; 72(1-2):95-102. PubMed ID: 24943098
[TBL] [Abstract][Full Text] [Related]
12. Oral cannabinoid-rich THC/CBD cannabis extract for secondary prevention of chemotherapy-induced nausea and vomiting: a study protocol for a pilot and definitive randomised double-blind placebo-controlled trial (CannabisCINV).
Mersiades AJ; Tognela A; Haber PS; Stockler M; Lintzeris N; Simes J; McGregor I; Olver I; Allsop DJ; Gedye C; Kirby AC; Morton RL; Fox P; Clarke S; Briscoe K; Aghmesheh M; Wong N; Walsh A; Hahn C; Grimison P
BMJ Open; 2018 Sep; 8(9):e020745. PubMed ID: 30209152
[TBL] [Abstract][Full Text] [Related]
13. Oromucosal delta9-tetrahydrocannabinol/cannabidiol for neuropathic pain associated with multiple sclerosis: an uncontrolled, open-label, 2-year extension trial.
Rog DJ; Nurmikko TJ; Young CA
Clin Ther; 2007 Sep; 29(9):2068-79. PubMed ID: 18035205
[TBL] [Abstract][Full Text] [Related]
14. Effect of ketamine combined with magnesium sulfate in neuropathic pain patients (KETAPAIN): study protocol for a randomized controlled trial.
Delage N; Morel V; Picard P; Marcaillou F; Pereira B; Pickering G
Trials; 2017 Nov; 18(1):517. PubMed ID: 29100524
[TBL] [Abstract][Full Text] [Related]
15. Meta-analysis of cannabis based treatments for neuropathic and multiple sclerosis-related pain.
Iskedjian M; Bereza B; Gordon A; Piwko C; Einarson TR
Curr Med Res Opin; 2007 Jan; 23(1):17-24. PubMed ID: 17257464
[TBL] [Abstract][Full Text] [Related]
16. [Efficacy, tolerability and safety of cannabinoids for chronic neuropathic pain: A systematic review of randomized controlled studies].
Petzke F; Enax-Krumova EK; Häuser W
Schmerz; 2016 Feb; 30(1):62-88. PubMed ID: 26830780
[TBL] [Abstract][Full Text] [Related]
17. Smoked cannabis for chronic neuropathic pain: a randomized controlled trial.
Ware MA; Wang T; Shapiro S; Robinson A; Ducruet T; Huynh T; Gamsa A; Bennett GJ; Collet JP
CMAJ; 2010 Oct; 182(14):E694-701. PubMed ID: 20805210
[TBL] [Abstract][Full Text] [Related]
18. Rationale and design of a randomized double-blind clinical trial in breast cancer: dextromethorphan in chemotherapy-induced peripheral neuropathy.
Martin E; Morel V; Joly D; Villatte C; Delage N; Dubray C; Pereira B; Pickering G
Contemp Clin Trials; 2015 Mar; 41():146-51. PubMed ID: 25636304
[TBL] [Abstract][Full Text] [Related]
19. Nabiximols in Chronic Neuropathic Pain: A Meta-Analysis of Randomized Placebo-Controlled Trials.
Dykukha I; Malessa R; Essner U; Überall MA
Pain Med; 2021 Apr; 22(4):861-874. PubMed ID: 33561282
[TBL] [Abstract][Full Text] [Related]
20. Analgesic efficacy and safety of the novel p38 MAP kinase inhibitor, losmapimod, in patients with neuropathic pain following peripheral nerve injury: a double-blind, placebo-controlled study.
Ostenfeld T; Krishen A; Lai RY; Bullman J; Baines AJ; Green J; Anand P; Kelly M
Eur J Pain; 2013 Jul; 17(6):844-57. PubMed ID: 23239139
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
